VBI Vaccines Inc.

OTCPK:VBIV.Q Stock Report

Market Cap: US$14.3k

VBI Vaccines Management

Management criteria checks 3/4

VBI Vaccines' CEO is Jeff Baxter, appointed in May 2016, has a tenure of 8.58 years. total yearly compensation is $893.55K, comprised of 78.1% salary and 21.9% bonuses, including company stock and options. directly owns 0.071% of the company’s shares, worth $10.14. The average tenure of the management team and the board of directors is 7.3 years and 6.9 years respectively.

Key information

Jeff Baxter

Chief executive officer

US$893.5k

Total compensation

CEO salary percentage78.1%
CEO tenure8.6yrs
CEO ownership0.07%
Management average tenure7.3yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

Sep 22

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

Sep 15

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

Sep 08

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09
Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

CEO Compensation Analysis

How has Jeff Baxter's remuneration changed compared to VBI Vaccines's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$84m

Dec 31 2023US$894kUS$698k

-US$94m

Sep 30 2023n/an/a

-US$115m

Jun 30 2023n/an/a

-US$119m

Mar 31 2023n/an/a

-US$120m

Dec 31 2022US$2mUS$678k

-US$113m

Sep 30 2022n/an/a

-US$111m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$605k

-US$70m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$2mUS$535k

-US$46m

Sep 30 2020n/an/a

-US$42m

Jun 30 2020n/an/a

-US$45m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$1mUS$500k

-US$55m

Sep 30 2019n/an/a

-US$63m

Jun 30 2019n/an/a

-US$62m

Mar 31 2019n/an/a

-US$66m

Dec 31 2018US$1mUS$465k

-US$64m

Sep 30 2018n/an/a

-US$56m

Jun 30 2018n/an/a

-US$50m

Mar 31 2018n/an/a

-US$43m

Dec 31 2017US$826kUS$450k

-US$39m

Compensation vs Market: Jeff's total compensation ($USD893.55K) is above average for companies of similar size in the US market ($USD650.40K).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.

CEO

Jeff Baxter (63 yo)

8.6yrs

Tenure

US$893,547

Compensation

Mr. Jeffery R. Baxter, also known as Jeff, FCMA, has been the Chief Executive Officer and President of VBI Vaccines Inc. since May 2016. Mr. Baxter has been the Chief Executive Officer and President of VBI...

Leadership Team

NamePositionTenureCompensationOwnership
Jeffery Baxter
President8.6yrsUS$893.55k0.071%
$ 10.1
Nell Beattie
CFO, Head of Corporate Development & Director1.7yrsno data0.0079%
$ 1.1
David Anderson
Chief Scientific Officer8.6yrsUS$564.56k0.017%
$ 2.5
Francisco Diaz-Mitoma
Chief Medical Officer8.8yrsUS$549.22k0.049%
$ 7.0
Nicole Anderson
Director of Corporate Communications & Investor Relationsno datano datano data
Athena Kartsaklis
Senior VP of Finance7.3yrsno datano data
Avi Mazaltov
Global Head of Manufacturing & GM of SciVac7.6yrsno data0.025%
$ 3.5
Misha Nossov
Senior VP of Global Commercial Supply Strategy & Head of Europe4.9yrsno datano data
T. Buckley
Senior Vice President of Business Development4.9yrsno datano data
John Dillman
Chief Commercial Officer2.4yrsno datano data

7.3yrs

Average Tenure

57.5yo

Average Age

Experienced Management: VBIV.Q's management team is seasoned and experienced (7.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jeffery Baxter
President8.6yrsUS$893.55k0.071%
$ 10.1
Nell Beattie
CFO, Head of Corporate Development & Director1.7yrsno data0.0079%
$ 1.1
Steven S. Gillis
Independent Chairperson of the Board8.6yrsUS$194.03k0.0098%
$ 1.4
Denis Burger
Member of Scientific Advisory Boardno datano datano data
Peter Patriarca
Member of Scientific Advisory Board6.9yrsno datano data
Stanley Plotkin
Member of Scientific Advisory Boardno datano datano data
Damian Braga
Chairperson of the Commercial Advisory Board & Independent Director4.8yrsUS$105.18k0%
$ 0
Michel De Wilde
Independent Director and Chair of Scientific & Clinical Advisory Board8.6yrsUS$107.68k0.0058%
$ 0.8
Blaine McKee
Independent Director5.9yrsUS$120.18k0%
$ 0
Joanne Cordeiro
Independent Director5.7yrsUS$127.68k0%
$ 0
Robert Pass
Member of Scientific Advisory Board6.9yrsno datano data
Adam Finn
Member of Scientific Advisory Board6.9yrsno datano data

6.9yrs

Average Tenure

68yo

Average Age

Experienced Board: VBIV.Q's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 11:11
End of Day Share Price 2024/12/27 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

VBI Vaccines Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Guyn KimBMO Capital Markets Equity Research
Kumaraguru RajaBrookline Capital Markets
John NewmanCanaccord Genuity